A case report describes the diagnostic and treatment course of one patient whose condition was initially diagnosed as primary immune thrombocytopenia (ITP). After immunosuppressive treatment, the patient's platelets temporarily rebounded. However, subsequent clinical and laboratory changes—including increased white blood cells and monocyte proportion—prompted further investigation. Bone marrow morphology and next-generation sequencing testing identified typical CMML-related mutations, leading to a final diagnosis of chronic myelomonocytic leukemia (CMML). The patient's condition stabilized after receiving decitabine chemotherapy. Safety and tolerability data for the treatments were not reported. The report notes that immunosuppressive treatment was given initially, but no comparator was described, and follow-up duration was not specified. Key limitations include the nature of a single case report, which lacks statistical analysis, a control group, and generalizability. The authors suggest clinical attention to potential clonal bone marrow diseases in ITP patients who are refractory or have a poor response to treatment. They note that early bone marrow morphological and molecular detection may help clarify diagnosis, guide treatment, and potentially improve prognosis. However, this remains a hypothesis based on one case, and no efficacy or safety conclusions can be drawn.
This report describes the detailed medical story of one patient. The patient first came to doctors with a low platelet count, a condition called immune thrombocytopenia (ITP). They received standard immunosuppressive treatment for ITP, and their platelet count improved temporarily. However, other blood cell counts later changed, prompting more investigation.
Doctors performed a bone marrow biopsy and advanced genetic testing. These tests found mutations typical of chronic myelomonocytic leukemia (CMML), which is a type of blood and bone marrow cancer. The patient's diagnosis was changed from ITP to CMML. Their treatment was switched to a chemotherapy drug called decitabine, and their condition stabilized.
It is crucial to understand this is a report of just one person's experience. The report does not mention any specific safety issues or side effects from the treatments. The main reason for caution is that one case cannot tell us how common this situation is. It does not prove that ITP leads to leukemia or that this diagnostic path is typical.
Readers should take from this that medicine can be complex, and diagnoses are sometimes refined over time as more information becomes available. For patients with similar conditions, this case highlights why doctors might order additional tests if the expected response to initial treatment is not seen. However, this single story does not change standard medical practice.
What this means for you: One patient's story shows how a blood cancer diagnosis can evolve, but it's just one case.
View Original Abstract ↓
ObjectiveTo explore the clinical characteristics, diagnosis and treatment process of a case initially diagnosed with primary immune thrombocytopenia (ITP) and finally diagnosed as chronic myeloid-monocytic leukemia (CMML).MethodsThe clinical manifestations, laboratory tests, bone marrow morphology, molecular genetic test results and treatment history of a CMML patient with thrombocytopenia as the first symptom were retrospectively analyzed.ResultsOne patient was initially diagnosed with immune thrombocytopenia (ITP). After receiving immunosuppressive treatment, the platelets temporarily rebounded, but subsequently the white blood cells increased, the proportion of monocytes increased, and typical CMML-related mutations were found in bone marrow morphology and NGS testing, and he was finally diagnosed as CMML. His condition stabilized after treatment with decitabine chemotherapy.ConclusionCMML can manifest as atypical thrombocytopenia in the early stage, which is delayed by the progression of ITP. Clinical attention should be paid to potential clonal bone marrow diseases in ITP patients who are refractory or have poor response to treatment. Early bone marrow morphological and molecular detection can help to clarify the diagnosis, guide treatment, and improve prognosis.
